Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.

British journal of cancer - 4 Jan 2011

Lamont F R, Tomlinson D C, Cooper P A, Shnyder S D, Chester J D, Knowles M A

Abstract excerpt

BACKGROUND: Activating mutations of FGFR3 are frequently identified in superficial urothelial carcinoma (UC) and increased expression of FGFR1 and FGFR3 are common in both superficial and invasive UC. METHODS: The effects of inhibition of receptor activity by three small molecule inhibitors (PD173074, TKI-258 and SU5402) were investigated in a panel of bladder tumour cell lines with known FGFR expression levels...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles
Share to Carcinoma, Transitional Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunoenzyme Techniques

Share to Pyrroles

Share to Quinolones

Share to Receptor, Fibroblast Growth Factor, Type 1

Share to Receptor, Fibroblast Growth Factor, Type 3

Share to Urothelium

Source

Open in PubMed Open full text

Identifiers

PMID: 21119661
DOI: 10.1038/sj.bjc.6606016
PMCID: PMC3039817

Genes

FGFR3
FGFR1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.PMID 21119661Read ↗

Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer.Semantic proximity Read ↗

FGFR Inhibitors in Urothelial Cancer: From Scientific Rationale to Clinical Development.Semantic proximity Read ↗

Fibroblast growth factor receptors-1 and -3 play distinct roles in the regulation of bladder cancer growth and metastasis: implications for therapeutic targeting.Semantic proximity Read ↗

1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest.Semantic proximity Read ↗

FGFR3 – a Central Player in Bladder Cancer Pathogenesis?Semantic proximity Read ↗

A place for precision medicine in bladder cancer: targeting the FGFRs.Semantic proximity Read ↗

Novel therapeutic targets in bladder cancer: mutation and expression of FGF receptors.Semantic proximity Read ↗

FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies.Semantic proximity Read ↗

Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target.Semantic proximity Read ↗

Resistance to Selective FGFR Inhibitors in FGFR- Driven Urothelial CancerSemantic proximity Read ↗

Fibroblast growth factor receptor (FGFR) gene: pathogenesis and treatment implications in urothelial carcinoma of the bladder.Semantic proximity Read ↗

Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.